BioCardia opened higher at $0.95, compared with its previous close of $0.92. In the last trading session, the stock traded between $0.66 and $0.95. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in BioCardia is now worth
$ 2.16
Resulting in a loss of
$ 97.84 (97.84%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.09 (-10.17%)
Day High
$0.95
Day Low
$0.66
Day Open
$0.95
Prev Close
$0.92
Volume
2,78,335
1W Return
-10.20%
1M Return
-18.82%
3M Return
-10.97%
6M Return
-25.41%
1Y Return
-37.74%
Fundamentals
Market Cap ($ Mn)
13
PE Ratio
-
PB Ratio
6.55
PEG Ratio
-
ROE
-4,316.89%
ROCE
-1,581.70%
EPS (TTM)
$-0.11
Investment Returns
1 Week
-10.20%
1 Month
-18.82%
3 Months
-10.97%
6 Months
-25.41%
9 Months
-29.83%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
13Nov
BioCardia reports Q3FY26 loss of $1.9 million, advances Japan PMDA path
Net loss widened to $1.9 million in Q3FY26 from $1.5 million in Q3FY25. Cash balance stands at $2.2 million, providing runway into 2027. Completed PMDA interactions for CardiAMP approval in Japan. Helix delivery system FDA De Novo submission planned for Q1 2027.
Today
6Nov
BioCardia completes PMDA process for CardiAMP in Japan
BioCardia completed PMDA application process for CardiAMP. Regulatory nod sought for ischemic heart failure treatment. Japan is a leading market for regenerative medicine. Milestone enables potential commercialization in Japan.
6 days ago
19Oct
BioCardia secures FDA acceptance for Helix catheter De Novo review
FDA accepted BioCardia's pre-submission package for Helix catheter clearance via De Novo pathway. Device is intended for therapeutic and diagnostic agent delivery to the heart. Substantive review and final discussion expected to occur this quarter.
24 days ago
1Oct
BioCardia resubmits FDA pre-submission for Helix Catheter approval
BioCardia completed a revised Pre-Submission to the FDA CDRH. Submission targets approval of the Helix Catheter for heart delivery. Device aims to deliver therapeutic and diagnostic agents. Process utilizes the FDA Q-Submission program.
1mo ago
22Sep
BioCardia regains compliance with Nasdaq $1 minimum bid price
BioCardia regained compliance with Nasdaq $1 minimum bid price requirement. Stock fell 10.19% in after-hours trading to $0.97. Market capitalization stands at approximately $16.35 million. Shares have declined 2.7% over the past 12 months.
1mo ago
24Aug
BioCardia finalizes FDA meeting minutes for Helix catheter De Novo pathway
BioCardia confirmed FDA finalized pre-submission meeting minutes for Helix catheter. Company plans follow-on pre-submission this quarter toward De Novo approval. Helix platform enables minimally invasive targeted delivery to heart tissue. Japan PMDA submission for CardiAMP therapy expected in Q4 2026.
